Compugen Ltd. (NASDAQ:
) today announced the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the fields of immunology and oncology, including its early stage pipeline of therapeutic proteins and monoclonal antibodies. The members of Compugen's SAB include four renowned translational scientists and clinicians in oncology and immunology. Listed in alphabetical order, the members are: Charles G. Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain B. McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, University of California Los Angeles; and Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation.
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “We are delighted to welcome this prestigious group of scientists to our Scientific Advisory Board for oncology and immunology, two therapeutic fields with substantial unmet medical needs and the primary fields of focus for Compugen. We very much appreciate their willingness and enthusiasm to collaborate with us as members of our SAB, which we view as further recognition of our growing presence in these important therapeutic areas.”
Dr. Cohen-Dayag continued, “Recently we announced the signing of our first agreement covering product candidates identified in our initial focused discovery program based on our unique predictive discovery infrastructure. This specific discovery effort was focused on immune checkpoint proteins, and this first agreement, with Bayer HealthCare, covered the development and commercialization of antibody therapeutics against two novel oncology targets for cancer immunotherapy.”
Dr. Cohen-Dayag concluded, “We are confident that the knowledge and experience of our newly formed SAB, which includes well-recognized world experts in the field of immune checkpoint proteins, will prove invaluable as we continue our development and commercialization efforts for our current product candidates, undertake additional focused discovery programs, and further enhance our predictive discovery infrastructure through deeper insights into the underlying science.”